Specific mutations in NOTCH1/2/4, TP53, and MYC, along with the activation of TGF-β receptor signaling pathways, may distinguish the clinical behavior of RDEB-cSCCs [11–13]. The gene discussed is NOTCH1; the disease is recessive dystrophic epidermolysis bullosa.